Harvesting Cells for Experimental Cancer Treatments

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
ClinicalTrials.gov Identifier:
NCT00068003
First received: September 4, 2003
Last updated: July 31, 2015
Last verified: April 2015
  Purpose

Background:

The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient.

Objective:

This study will collect white blood cells from normal volunteers and white blood cells and/or tumor cells, from patients who have been screened for and are eligible for a NCI Surgery Branch treatment protocol. The cells collected from normal volunteers will be used as growth factors for the cells during the period of laboratory growth. The cells and/or tumor from patients will be used to make the cell treatment product.

Eligibility:

Patients must be eligible for a NCI Surgery Branch Treatment Protocol

Normal Volunteers must meet the criteria for blood donation

Design

Both patients and normal Volunteers will undergo apheresis. Patients will then undergo further testing as required by the treatment protocol.

There is no required follow up for normal volunteers.


Condition
Melanoma
Metastatic Melanoma
Metastatic Cancer

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • To obtain autologous blood, stem cells and/or tumor tissue from patients currently with cancer for laboratory analysis and ex vivo generation of autologous anti-tumor lymphocytes for future enrollment on a Surgery Branch adoptive cell therapy cl... [ Time Frame: 15 years ] [ Designated as safety issue: No ]

Enrollment: 1659
Study Start Date: August 2003
Detailed Description:

BACKGROUND:

There are numerous clinical trials underway in the Surgery Branch, NCI in which patients are administered autologous lymphocytes with anti-tumor activity generated from either peripheral blood mononuclear cells (PBMC) or tumor infiltrating lymphocytes (TIL). All adoptive cell therapy protocols require that certain cell criteria be evaluated and met prior to enrollment.

OBJECTIVES:

  • To obtain autologous blood, stem cells and/or tumor tissue from patients currently with cancer for laboratory analysis and ex vivo generation of autologous anti-tumor lymphocytes for future enrollment on a Surgery Branch adoptive cell therapy clinical trial, or for research purposes.
  • To obtain autologous blood from patients with a history of cancer who currently have no evidence of disease for research purposes.
  • To obtain allogeneic PBMC via apheresis, or blood samples from normal volunteers for use in generating anti-tumor patient lymphocytes ex vivo, or for research.
  • To obtain PBMC via apheresis, blood samples, and skin biopsies from subjects with spontaneous vitiligo for research purposes.
  • To conduct genomic, proteomic and immunologic research studies on samples collected.

ELIGIBILITY:

Patients with cancer must be 16 years of age or older and meet the laboratory safety testing for infection included in all the cell therapy treatment trials.

Normal volunteers must meet the safety evaluation criteria established by the FDA for donation of blood products including HIV, HCV, HTLV, CMV, HBsAg, HBc, Trypanosoma cruzi, syphilis, and West Nile Virus. They must also meet the strict behavioral and medical history requirements.

Patients with a history of cancer who currently have no evidence of disease and subjects with spontaneous vitiligo must meet the laboratory safety testing for infection and other criteria outlined in the protocol.

DESIGN:

Once a cancer patient is determined to be a potential candidate for one of the Surgery Branch clinical trials, they will undergo an apheresis and/or tumor resection for future treatment and/or research purposes. In addition, this protocol will allow for the pheresis of normal volunteers for allogeneic PBMC used in generating autologous anti-tumor lymphocytes in the laboratory, or for research purposes. This protocol will also allow for apheresis of patients with a history of cancer, and apheresis and , blood samples and skin biopsies in subjects with spontaneous vitiligo.

No treatments, investigational or standard therapy, will be administered on this protocol.

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER:

INCLUSION CRITERIA:

  • Patients must have a form of cancer currently being studied with adoptive cell therapies in the Surgery Branch.
  • Able to understand and sign the Informed Consent Document.
  • Patients must be greater than or equal to 16 years of age.
  • Clinical performance status of ECOG 0 or 1.
  • Life expectancy of greater than three months.
  • Seronegative for HIV (The experimental treatments being evaluated depend upon an intact immune system. Patients who are HIV seropositive can have decreased immune competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities).
  • Seronegative for hepatitis B surface antigen and seronegative for antibody to hepatitis C. If hepatitis C antibody test is positive, then patients must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.
  • If Surgery is required to obtain TIL for cell acquisition, the expected procedure must be associated with minimal morbidity and minimal hospitalization.

EXCLUSION CRITERIA:

  • Active systemic infections, coagulation disorders, or other major medial illnesses of the cardiovascular, respiratory, or immune system.
  • Patients who cannot give proper informed consent to the adoptive cell experimental therapy due to an active psychiatric disorder or inability to understand the nature of the proposed therapy and attendant risk.

ELIGIBILITY CRITERIA FOR NORMAL DONORS:

INCLUSION CRITERIA:

  • Normal donors must be greater than or equal to 18 years of age.
  • Seronegative for HBsAg, Anti-HBc, Anti-HCV, Anti-HIV-1/2, HIV- 1/HCV/HBV NAT, anti-HTLV-1/2, RPR, T. cruzi, and West Nile Virus NAT
  • Normal donors must meet the strict behavioral and medical history requirements

EXCLUSION CRITERIA:

  • Has had babesiosis.
  • Is at risk or has Creutzfeld-Jakob Disease.
  • Is on steroid therapy or any other medication or has received vaccination that might interfere with cell preparation per Principal Investigator s discretion.
  • Has ongoing illness that would cause harm to the volunteer during the apheresis procedure as determined by the Principal Investigator.
  • Has had yellow jaundice, liver disease, or hepatitis since the age of 11
  • Has uncontrolled diabetes
  • Has a hematologic malignancy or any bleeding abnormalities
  • Has received any type of organ transplant in the past 12 months.
  • Has undergone xenotransplantaion at any time.
  • Has received a dura mater graft.
  • If female, has been pregnant in the last six weeks
  • Has had body piercing or tatoos within the past year
  • Has spent time outside the United States to a restricted country
  • Has participated in any high-risk activities

Eligibility Criteria for Subjects with Spontaneous Vitiligo and for Patients with a history of cancer who currently have no evidence of disease.

INCLUSION CRITERIA:

- Greater than or equal to 18 years of age.

EXCLUSION CRITERIA:

- Has ongoing illness that would cause harm to the volunteer during the apheresis procedure as determined by the Principal Investigator.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00068003

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Investigators
Principal Investigator: Steven A Rosenberg, M.D. National Cancer Institute (NCI)
  More Information

Additional Information:
Publications:
Responsible Party: National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
ClinicalTrials.gov Identifier: NCT00068003     History of Changes
Obsolete Identifiers: NCT00897195
Other Study ID Numbers: 030277, 03-C-0277
Study First Received: September 4, 2003
Last Updated: July 31, 2015
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Adoptive Cell Therapy
Screening
Cell Harvest
Blood
Tumor Tissue

Additional relevant MeSH terms:
Melanoma
Neoplasm Metastasis
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neoplastic Processes
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Pathologic Processes

ClinicalTrials.gov processed this record on September 03, 2015